An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 2001

Primary Completion Date

August 31, 2004

Conditions
Haemophilia A
Interventions
BIOLOGICAL

Optivate® (Human Coagulation Factor VIII)

Trial Locations (11)

Unknown

Klinika Haematologii, Akademia Medyczna w Bialymstokiu, ul., Bialystok

Klinika Haematologii, Akademia Medyczna w Gdansku, u., Gdansk

Klinika Haematologii, Akademia Medyczna w Lodzi, ul., Lodz

Klinika Haematologii, Akademia Medyczna w Lublinie, ul., Lublin

Klinika Haematologii, Akademia Medyczna w Poznaniu, ul., Poznan

Klinika Haematologii, Akademia Medyczna w Wroclawiu, ul., Wroclaw

CB2 2QQ

Haemophilia Centre, Addenbrooke's Hospital, Hills Road, Cambridge

M13 9WL

Haemophilia Centre, University Department of Haemophilia Manchester Royal Infirmary, Manchester

NG7 2UH

Haemophilia Centre, University Hospital, Queen's Medical Centre, Clifton Boulevard, Nottingham

S10 2JF

Sheffield Haemophilia & Thrombosis Centre, Royal Hallamshire Hospital, Glossop Road, Sheffield

SO16 6YD

Haemophilia Centre, Southampton General Hospital, Tremona Road, Southampton

Sponsors
All Listed Sponsors
lead

Bio Products Laboratory

OTHER